Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne MedicinesFRA:49BA +0.75%77 Cyclically Adjusted PS Ratio is 17.26 as of Jul. 17, 2026, which is 8% below its 10-year median of 18.69. GuruFocus rates FRA:49BA with a GF Score™ of 77/100 and a GF Value™ of €314.38 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 538 Biotechnology companies, BeOne Medicines ranks worse than 76.95% on this metric.
The historical rank and industry rank for BeOne Medicines's Cyclically Adjusted PS Ratio or its related term are showing as below:
FRA:49BA'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.12 Med: 18.69 Max: 23.6
Current: 16.94
During the past years, BeOne Medicines's highest Cyclically Adjusted PS Ratio was 23.60. The lowest was 14.12. And the median was 18.69.
FRA:49BA's Cyclically Adjusted PS Ratio is ranked worse than 76.95% of 538
companies
in the Biotechnology industry
Industry Median: 5.825
vs FRA:49BA: 16.94
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
BeOne Medicines's adjusted revenue per share data for the three months ended in Mar. 2026 was €11.308. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €15.64 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
BeOne Medicines (FRA:49BA) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
BeOne Medicines Cyclically Adjusted PS Ratio Related Terms
BeOne Medicines Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines Cyclically Adjusted PS Ratio Chart
FRA:49BA vs MRNA, RPRX, ROIV: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Cyclically Adjusted PS Ratio falls into.
BeOne Medicines Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
BeOne Medicines's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 17.26 mean?
BeOne Medicines (FRA:49BA) has a Cyclically Adjusted PS Ratio of 17.26 as of Jul. 17, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on BeOne Medicines and its competitors. This is near median its historical median of 18.69. Over the past decade, BeOne Medicines' Cyclically Adjusted PS Ratio has ranged from 14.12 to 23.60. According to the industry distribution chart, BeOne Medicines ranks #414 out of 538 companies in the Biotechnology industry, placing it in the top 77%.
Is BeOne Medicines' Cyclically Adjusted PS Ratio too high?
BeOne Medicines' current Cyclically Adjusted PS Ratio of 17.26 is near median its 10-year median of 18.69. Over the past 10 years, this metric has ranged from a low of 14.12 to a high of 23.60. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.83. BeOne Medicines' value of 17.26 is 196.3% above this industry median. Based on the distribution chart, BeOne Medicines ranks #414 out of 538 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cyclically Adjusted PS Ratio compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #414 out of 538 companies for Cyclically Adjusted PS Ratio. This places BeOne Medicines in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.83. BeOne Medicines' value of 17.26 is 196.3% above this benchmark. Historically, BeOne Medicines' own Cyclically Adjusted PS Ratio has ranged from 14.12 to 23.60 over the past decade. While the company's 10-year median is 18.69 vs. the industry median of 5.83, BeOne Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.83, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Cyclically Adjusted PS Ratio of 17.26 is 196.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Cyclically Adjusted PS Ratio is 17.26, which is near median its own 10-year median of 18.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (FRA:49BA) is currently considered Modestly Undervalued. The stock's GF Value™ is €314.38, compared to a current price of €270.00 — trading 14.1% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 17.26, which is near median its 10-year median of 18.69 and 196.3% above the Biotechnology industry median of 5.83. BeOne Medicines' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For BeOne Medicines (FRA:49BA), the current Cyclically Adjusted PS Ratio is 17.26 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (FRA:49BA) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of €270.00 is trading 14.1% below its estimated GF Value™ of €314.38.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for FRA:49BA:
Cyclically Adjusted PS Ratio: 17.26 (near median its 10-year median of 18.69)
GF Value™: €314.38 vs. price of €270.00 (14.1% below fair value)
Industry Position: 196.3% above the Biotechnology median (#414 of 538)
No single metric tells the full story. See the FRA:49BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for FRA:49BA
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:49BA has been successfully added to your 
